Breaking Finance News

Zacks Investment Research upgraded Neurometrix Inc (NASDAQ:NURO) to Hold in a report released today.

Having a price of $1.54, Neurometrix Inc (NASDAQ:NURO) traded 1.30% higher on the day. With the last close down 7.18% relative to the two hundred day average, compared to the S&P 500 Index which has decreased -0.01% over the same time period. Neurometrix Inc has registered a 50-day average of $1.48 and 200-day average of $1.68. Trade volume was was up over the average, with 301,851 shares of NURO changing hands over the typical 91,628 shares.

Zacks Investment Research has upgraded Neurometrix Inc(NASDAQ:NURO) to Hold in a report released 9/20/2016.

Recent Performance Chart:

Neurometrix Inc (NASDAQ:NURO)

A total of 2 equity analysts have issued a report on Neurometrix Inc. Zero rate the company a strong buy, one analyst rate the stock a buy, 0 analysts rate the stock a hold, 0 rate the stock to underperform, and lastly 0 firmsrate the company as sell with an average target of $4.75

Neurometrix Inc has a one-year low of $1.35 and a one-year high of $3.80 . NURO’s market cap is presently $0.0.

General Information About Neurometrix Inc (NASDAQ:NURO)

NeuroMetrix, Inc. (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain, nerve diseases and sleep disorders. The Company operates through the sale of medical equipment and consumables segment. Its products are sold in the United States and selected overseas markets. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The Company’s products consist of a medical device used in conjunction with a consumable electrode or biosensor. Its products include Quell, which is a wearable device for relief of chronic intractable pain; SENSUS, which is a prescription neuro-stimulation device; DPNCheck, which is a nerve conduction test that is used to evaluate systemic neuropathies, and ADVANCE System, and which is a platform for the performance of nerve conduction studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.